Loading
Surgeon-scientist who led IMpassion031 and studies of surgery de-escalation after neoadjuvant immunotherapy.
Elizabeth Mittendorf led IMpassion031, showing neoadjuvant atezolizumab plus chemotherapy raises pathological complete response in TNBC regardless of PD-L1 status, and ran the early HER2 peptide vaccine trials. As a breast surgeon she leads Alliance trials asking whether axillary surgery and radiotherapy can be omitted after excellent neoadjuvant response. She directs breast immuno-oncology at Dana-Farber.
Shares Atezolizumab, Triple-negative breast cancer (TNBC), Immune checkpoint inhibitors and the tags tnbc, immunotherapy.
Shares Cancer Immunology Research, Triple-negative breast cancer (TNBC).
Shares Dana-Farber Brigham Cancer Center, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Cancer Immunology Research, Immune checkpoint inhibitors.
Shares Cancer Immunology Research, Immune checkpoint inhibitors.
Shares Dana-Farber Brigham Cancer Center, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Sentinel lymph node biopsy, Triple-negative breast cancer (TNBC) and the tag surgery.
Shares Immune checkpoint inhibitors and the tags surgery, immunotherapy.